Lorenzo Dottorini

Very happy and proud to share our @JCO_ASCO publication. Accordin to our research no advantage in OS and DFS adding oxaliplatin to adjuvant stage III colorectal cancer in older patients. ascopubs.org/doi/abs/10.120…

@Crypto_Twittier Anche i prezzi delle alt li avevi previsti benissimo.......aspettiamo ancora la tua previsione su Brett.......🤡🤡🤡🤡

#Bitcoin - In this exact order. I predicted where we would stop and the price we would stay above. I painted a picture to show what I expected to happen until Q4. After holding $58K, we are now "slowly" heading back up to $81K in the exact range I predicted. To be continued..🥂

@Crypto_Twittier Ma va caghèr va

#Bitcoin - Exactly As Predicted! $98k was hit and now we are taking the next leg down. My plan is to continue shorting $Btc all the way down to $40k and possibly even lower.... 🥂

Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next. Co-authored by @faupe. Read the full article. brnw.ch/21wZjkE #ImmunoOnc

Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma geriatriconcology.net/article/S1879-… @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #Geriatric8 #CGA

Outstanding results!

@nicolobattisti @faupe @OncoGeriatria @aluciani73 @giandodm1 @SIOGorg @YoungSIOG @WilliamDale_MD @GrantWilliamsMD @OncBrothers

Adjuvant CDK4/6 inhibitors in older patients: safe and effective or to be used with caution? We aimed to answer in our last study I'm very happy to share. As always special thanks to @JGeriOnc staff. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

A must-read. Congrats to the authors. @SIOGorg @YoungSIOG

@oncology_bg @Medscape I absolutely agree. Many examples of studies could be done about this, especially if we talk about older patients. Great job.

Every time they approve a drug based on non-survival endpoint, they give us some excuse. I have collected those excuses. There are seven of them. In this new column in @Medscape , I and Dr. Sharon Batt, a cancer survivor and regulatory science expert, list these seven arguments and specifically respond to each of them to demonstrate why OS still remains the most patient centric endpoint for cancer drug trials. Please do read. This is NOT another “surrogates are bad” paper. We specifically address the concerns raised against OS. I hope you’ll be convinced. medscape.com/viewarticle/wh…

Outstanding paper! Congrats to @Icro_Meattini and colleagues thelancet.com/journals/lanon…

@SirRobArtII1 Meeeee my friend 😃😃👍🏻👍🏻

Young oncologists speaking of Geriatric Oncology issues AIOTE National Meeting

First day AIOTE National Meeting Siracusa

@JGeriOnc @LeanaChien @SunCanlan @DanengLi @WilliamDale_MD @rochgerionc @myCARG Congrats to the authors!

Geriatric Assessment-driven INterventions among Hospitalized older adults with cancer (GAIN-HOSP), a prospective pilot study geriatriconcology.net/article/S1879-… @LeanaChien @SunCanlan @DanengLi @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Aging

Outstanding paper! Hospitalized older patients need more attentions! Congrats to the authors

There are just a few days until #ESMO24! We're looking forward to seeing many colleagues and friends. Stop by the #SIOG stand S314 to say hi! Psst. We're offering special ESMO24 discounts on SIOG memberships. Spread the word. See you then!

Absolute outstanding result! Once again the demonstration that in older patients sometimes "less is more". Congrats to the authors. @SIOGorg @YoungSIOG

Congrats to @faupe and colleagues. Vitamin D supplementation reduce total cancer mortality! Strong evidence for thyroid and renal cancer, highly suggestive evidence for many others. Maybe Vit D is deeply underestimated in oncology treatment and prevention? authors.elsevier.com/c/1jftO8Yy15AN…

3- Constructive feedback is always welcome @YoungSIOG @SIOGorg @G_LipositsMD @nicolobattisti @WilliamDale_MD @faupe @rochgerionc

2- We analyzed data from the most significant trials on CSPC and tried to explore the real advantage of a combination therapy from the beginning. Our question is: are we sure that a combination therapy is beneficial for ALL patients? Especially for older patients?

1-Maybe not everyone will agree, but I want to share this article we just published which reflects our thoughts about using early combination therapy rather than sequential in hormone-sensitive prostate cancer. authors.elsevier.com/c/1jdJp5YR3Ced…